|
DOSAGE
|
Conjunctivitis: Day 1: 1 gtt q2hrs while awake (up to 8 times), Day 2-7: 1 gtt BID-QID while awake
|
|
Low risk of vision loss: 1 gtts q1-2hr + Optional add on tobramycin or ciprofloxacin ung qHS
|
|
Moderate risk of vision loss: Loading dosage q5min for 5 doses, then q30min until midnight, then q1hr
|
|
Vision-threatening: Consider fortified tobraymycin or gentamicin (15 mg/ml) q1hr, alternating with fortified cefazolin (50mg/ML) or vancomycin (25mg/mL) q1hr.
|
|
INDICATIONS
|
ZYMAXID® is indicated for the treatment of bacterial conjunctivitis, off label for corneal ulcer.
|
|
MECHANISM OF ACTION
|
fluoroquinolone (4th): Binds bacterial DNA gyrase topoisomerase II and topoisomerase IV
|
|
MICROBIOLOGY
|
Active against a very broad range of gram negative and positive Organisms. Gatifloxacin has been shown to be active against most isolates of the following organisms both microbiologically and clinically, in conjunctival infections: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group* Streptococcus oralis* Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae
|
|
CONTRAINDICATIONS & WARNINGS
|
ZYMAXID® is contraindicated in patients with a history of hypersensitivity to gatifloxacin, to other quinolones, or to any of the components in this medication
|
|
PEDIATRIC USE
|
ZYMAXID® has been demonstrated in clinical trials to be safe and effective for the treatment of bacterial conjunctivitis in pediatric patients one year or older
|
|
PREGNANCY
|
Category C: There are no available data on the use of ZYMAXID® in pregnant women to inform a drug-associated risk. Administration of oral gatifloxacin to pregnant rats and rabbits throughout organogenesis did not produce adverse development outcomes at clinically relevant doses. Administration of gatifloxacin to rats during late gestation through lactation did not produce adverse maternal, fetal or neonatal effects at clinically relevant doses.
|
